GlycoMimetics

GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2003
Size (employees)
42 (est)
GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Key People/Management at GlycoMimetics

Brian Hahn

Brian Hahn

Chief Financial Officer
John Baldwin

John Baldwin

Director
Michael Henos

Michael Henos

Director
Franklin H. Top

Franklin H. Top

Director
William Gust

William Gust

Director
M. James Barrett

M. James Barrett

Chairman of the Board of Directors

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville
Rockville, US (HQ)
9708 Medical Center Dr

GlycoMimetics Financials and Metrics

GlycoMimetics Financials

GlycoMimetics's revenue was reported to be $18.5 k in FY, 2016
USD

Net income (Q3, 2017)

(24 m)

Market capitalization (13-Nov-2017)

246.4 m

Cash (30-Sep-2017)

112.9 m
GlycoMimetics's current market capitalization is $246.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

15 m20.1 m18.5 k

Revenue growth, %

34%(100%)

EBIT

(11.1 m)(12.8 m)

EBIT margin, %

(74%)(64%)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)(24 m)
USDFY, 2014FY, 2015FY, 2016

Cash

55.2 m46.8 m40 m

Accounts Receivable

13.6 m

Inventories

916.2 k441.8 k478.5 k

Current Assets

56.1 m47.2 m40.5 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

57 m66.2 m61.4 m46.6 m40.2 m53.8 m38.8 m53.1 m45.3 m34.6 m119.1 m112.9 m

Accounts Receivable

20 m

Inventories

1 m

Current Assets

57.7 m67.1 m61.9 m47.3 m60.8 m54.5 m39.5 m54.5 m46.5 m35.3 m119.7 m113.9 m
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (11.1 m)(12.8 m)(31.8 m)

    Depreciation and Amortization

    158.7 k191.5 k190.5 k

    Accounts Receivable

    (1.9 m)(1.7 m)(1.9 m)

    Inventories

    1.7 m474.4 k(36.7 k)
    USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (5.1 m)2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)(16.1 m)(24 m)

    Depreciation and Amortization

    34.6 k73.5 k114.3 k44.2 k90.5 k142.4 k47.2 k93.9 k139.7 k54.3 k123.9 k

    Accounts Receivable

    (20 m)

    Inventories

    1 m
      Y, 2017

      Financial Leverage

      1.1 x
      Show all financial metrics

      GlycoMimetics Market Value History

      GlycoMimetics's Web-traffic and Trends

      GlycoMimetics Company Life and Culture

      You may also be interested in